A citation-based method for searching scientific literature

Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Heejung Chae, Eo Jin Kim, Mee-Sun Moon, Yoon-Koo Kang. Cancer Res Treat 2021
Times Cited: 3







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
66

A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models.
Dong Hoe Koo, Baek-Yeol Ryoo, Hwa Jung Kim, Min-Hee Ryu, Sung-Sook Lee, Jung-Hwa Moon, Heung-Moon Chang, Jae-Lyun Lee, Tae Won Kim, Yoon-Koo Kang. Cancer Chemother Pharmacol 2011
53
66

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
309
66

Is noncurative gastrectomy always a beneficial strategy for stage IV gastric cancer?
Chang Min Lee, In Keun Choi, Jong-Han Kim, Da Won Park, Jun Suk Kim, Seong-Heum Park. Ann Surg Treat Res 2017
4
33

Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Daisuke Takahari, Narikazu Boku, Junki Mizusawa, Atsuo Takashima, Yasuhide Yamada, Takayuki Yoshino, Kentaro Yamazaki, Wasaburo Koizumi, Kazutoshi Fukase, Kensei Yamaguchi,[...]. Oncologist 2014
40
33

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Kazumasa Fujitani, Han-Kwang Yang, Junki Mizusawa, Young-Woo Kim, Masanori Terashima, Sang-Uk Han, Yoshiaki Iwasaki, Woo Jin Hyung, Akinori Takagane, Do Joong Park,[...]. Lancet Oncol 2016
357
33

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
401
33

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Salah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, Harald Schmalenberg, Stephan Hollerbach, Ralf Hofheinz, Volker Rethwisch, Gernot Seipelt, Nils Homann, Gerhard Wilhelm,[...]. J Clin Oncol 2008
538
33

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Sung Sook Lee, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Hye-Jin Kang, Woo Kun Kim, Jung Shin Lee, Yoon-Koo Kang. Jpn J Clin Oncol 2007
35
33

Cancer-related inflammation and treatment effectiveness.
Connie I Diakos, Kellie A Charles, Donald C McMillan, Stephen J Clarke. Lancet Oncol 2014
33

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Y-K Kang, W-K Kang, D-B Shin, J Chen, J Xiong, J Wang, M Lichinitser, Z Guan, R Khasanov, L Zheng,[...]. Ann Oncol 2009
556
33

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
Yumiko Ota, Daisuke Takahari, Takeshi Suzuki, Hiroki Osumi, Izuma Nakayama, Akira Oki, Takeru Wakatsuki, Takashi Ichimura, Mariko Ogura, Eiji Shinozaki,[...]. Cancer Chemother Pharmacol 2020
32
33

Gastric cancer.
Eric Van Cutsem, Xavier Sagaert, Baki Topal, Karin Haustermans, Hans Prenen. Lancet 2016
33


Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Jung Hun Kang, Soon Il Lee, Do Hyoung Lim, Keon-Woo Park, Sung Yong Oh, Hyuk-Chan Kwon, In Gyu Hwang, Sang-Cheol Lee, Eunmi Nam, Dong Bok Shin,[...]. J Clin Oncol 2012
459
33


Prediction of Cancer Incidence and Mortality in Korea, 2020.
Kyu-Won Jung, Young-Joo Won, Seri Hong, Hyun-Joo Kong, Eun Sook Lee. Cancer Res Treat 2020
85
33

Capecitabine and oxaliplatin for advanced esophagogastric cancer.
David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman. N Engl J Med 2008
33

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Jaffer A Ajani, Wuilbert Rodriguez, Gyorgy Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, Vera Gorbunova, Ihor Vynnychenko, August Garin, Istvan Lang, Silvia Falcon. J Clin Oncol 2010
419
33

Recent Developments of Systemic Chemotherapy for Gastric Cancer.
Hiroyuki Arai, Takako Eguchi Nakajima. Cancers (Basel) 2020
25
33

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.
J Lee, T Lim, J E Uhm, K W Park, S H Park, S C Lee, J O Park, Y S Park, H Y Lim, T S Sohn,[...]. Ann Oncol 2007
137
33

Decision curve analysis: a novel method for evaluating prediction models.
Andrew J Vickers, Elena B Elkin. Med Decis Making 2006
33

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
T Grenader, T Waddell, C Peckitt, J Oates, N Starling, D Cunningham, J Bridgewater. Ann Oncol 2016
62
33

Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis.
Emil Ter Veer, Jessy Joy van Kleef, Sandor Schokker, Stephanie O van der Woude, Marety Laarman, Nadia Haj Mohammad, Mirjam A G Sprangers, Martijn G H van Oijen, Hanneke W M van Laarhoven. Eur J Cancer 2018
20
33

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.
Graeme J K Guthrie, Kellie A Charles, Campbell S D Roxburgh, Paul G Horgan, Donald C McMillan, Stephen J Clarke. Crit Rev Oncol Hematol 2013
843
33


Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Dong Hoe Koo, Min-Hee Ryu, Baek-Yeol Ryoo, Jinjoo Seo, Mi-Yeon Lee, Heung-Moon Chang, Jae-Lyun Lee, Sung-Sook Lee, Tae Won Kim, Yoon-Koo Kang. Gastric Cancer 2015
21
33


HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild,[...]. J Clin Oncol 2021
27
33

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
33

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto, Takahiro Kinoshita. World J Clin Cases 2019
24
33

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
Takeru Wakatsuki, Noriko Yamamoto, Takeshi Sano, Keisho Chin, Hiroshi Kawachi, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Izuma Nakayama, Hiroki Osumi,[...]. J Gastroenterol 2018
45
33

HER2-positive gastric cancer.
Narikazu Boku. Gastric Cancer 2014
201
33

Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Sook Ryun Park, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang. Eur J Cancer 2016
55
33

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.
Josef Rüschoff, Manfred Dietel, Gustavo Baretton, Susanne Arbogast, Axel Walch, Geneviéve Monges, Marie-Pierre Chenard, Frédérique Penault-Llorca, Iris Nagelmeier, Werner Schlake,[...]. Virchows Arch 2010
346
33

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018.
Seri Hong, Young-Joo Won, Jae Jun Lee, Kyu-Won Jung, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo. Cancer Res Treat 2021
99
33

Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Chan-Young Ock, Keun-Wook Lee, Jin Won Kim, Jin-Soo Kim, Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Woo Ho Kim,[...]. Clin Cancer Res 2015
47
33


Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. Arch Pathol Lab Med 2014
709
33


Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee. Eur J Cancer 2013
115
33


Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study.
Matteo Franchi, Roberta Tritto, Lorena Torroni, Chiara Reno, Carlo La Vecchia, Giovanni Corrao. Cancers (Basel) 2020
5
33

HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
285
33

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Shusuke Yagi, Takeru Wakatsuki, Noriko Yamamoto, Keisho Chin, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Izuma Nakayama, Hiroki Osumi, Eiji Shinozaki,[...]. Gastric Cancer 2019
28
33

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. Histopathology 2008
830
33


HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
276
33

Effect of adjusted positioning on gastric distention and fluid distribution during CT gastrography.
Se Hyung Kim, Jeong Min Lee, Joon Koo Han, Jae Young Lee, Han Kwang Yang, Hyuk-Joon Lee, Kyung-Sook Shin, Byung Ihn Choi. AJR Am J Roentgenol 2005
24
33

Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.
Ning Li, Wenying Deng, Jie Ma, Bing Wei, Kang Guo, Wei Shen, Yanping Zhang, Suxia Luo. Med Oncol 2015
70
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.